» Articles » PMID: 24552626

Monitoring M-proteins in Patients with Multiple Myeloma Using Heavy-chain Variable Region Clonotypic Peptides and LC-MS/MS

Overview
Journal J Proteome Res
Specialty Biochemistry
Date 2014 Feb 21
PMID 24552626
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Multiple myeloma is a disease characterized by a clonal expansion of plasma cells that secrete a monoclonal immunoglobulin also referred to as an M-protein. In the clinical laboratory, protein electrophoresis (PEL), immunofixation electrophoresis (IFE), and free light chain nephelometry (FLC) are used to detect, monitor, and quantify an M-protein. Here, we present an alternative method based on monitoring a clonotypic (i.e., clone-specific) peptide from the M-protein heavy chain variable region using LC-MS/MS. Tryptic digests were performed on IgG purified serum from 10 patients with a known IgG M-protein. Digests were analyzed by shotgun LC-MS/MS, and the results were searched against a protein database with the patient specific, heavy chain variable region gene sequence added to the database. In all 10 cases, the protein database search matched multiple clonotypic peptides from each patient's heavy chain variable region. The clonotypic peptides were then used to quantitate the amount of M-protein in patient serum samples using selected reaction monitoring (SRM) on a triple quadrupole mass spectrometer. The response for the clonotypic peptide observed by SRM correlated with the M-protein observed by PEL. In addition, the clonotypic peptide was clearly observed by SRM in samples that were negative by IFE and FLC. Monitoring clonotypic peptides using SRM has the capacity to redefine clinical residual disease because of its superior sensitivity and specificity compared with current analytical methods.

Citing Articles

Endogenous monoclonal immunoglobulins analyzed using the EXENT® solution and LC-MS.

Barnidge D, Troske D, North S, Wallis G, Perkins M, Harding S J Mass Spectrom Adv Clin Lab. 2024; 32:31-40.

PMID: 38405412 PMC: 10891330. DOI: 10.1016/j.jmsacl.2024.02.002.


Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM).

Fan H, Wang B, Shi L, Pan N, Yan W, Xu J Clin Cancer Res. 2024; 30(6):1131-1142.

PMID: 38170583 PMC: 10940853. DOI: 10.1158/1078-0432.CCR-23-2767.


Advances in neuroproteomics for neurotrauma: unraveling insights for personalized medicine and future prospects.

Kobeissy F, Goli M, Yadikar H, Shakkour Z, Kurup M, Haidar M Front Neurol. 2023; 14:1288740.

PMID: 38073638 PMC: 10703396. DOI: 10.3389/fneur.2023.1288740.


Liquid biopsy and blood-based minimal residual disease evaluation in multiple myeloma.

Gozzetti A, Bocchia M Oncol Res. 2023; 31(3):271-274.

PMID: 37305387 PMC: 10229300. DOI: 10.32604/or.2023.028668.


GWAS-Identified Variants for Obesity Do Not Influence the Risk of Developing Multiple Myeloma: A Population-Based Study and Meta-Analysis.

Sanchez-Maldonado J, Cabrera-Serrano A, Chattopadhyay S, Campa D, Garrido M, Macauda A Int J Mol Sci. 2023; 24(7).

PMID: 37047000 PMC: 10094344. DOI: 10.3390/ijms24076029.